EMA recommends daraxonrasib for metastatic pancreatic cancer after a fast-tracked phased review
- On 15 October 2026 the EMA recommended authorising Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma.
- Daraxonrasib is an oral RAS inhibitor for adults who have had at least one previous treatment.
- In a 500-patient study, median survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy.
- The daraxonrasib assessment took less than 150 days thanks to a phased review.
The European Medicines Agency's human medicines committee recommended on 15 October 2026 that Rasonque (daraxonrasib) be authorised in the EU. It is an oral treatment for adults with metastatic pancreatic adenocarcinoma who have had at least one previous treatment, a group with few options and a poor outlook, for whom chemotherapy is of limited benefit and highly toxic.
How it works
Daraxonrasib is a RAS inhibitor. RAS proteins control cell growth and survival, and in pancreatic cancer RAS mutations keep them permanently switched on. The drug binds a protein called cyclophilin A, and the resulting complex attaches to RAS and blocks it.
Results
The phase 3 study enrolled 500 patients whose disease had worsened after prior treatment; 92% had a confirmed RAS G12 mutation. Median overall survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months. The most common side effects were diarrhoea, rash, mouth inflammation, nausea and vomiting.
A faster review
Under its Cancer Medicines Pathfinder project, the EMA assessed the data in phases from early July 2026, cutting the review to under 150 days versus about a year for a standard evaluation. The opinion now goes to the European Commission for a fast-tracked decision.
Sources: European Medicines Agency (EMA), EMA — CHMP meeting highlights, October 2026
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is Rasonque (daraxonrasib)?
Rasonque (daraxonrasib) is an oral RAS inhibitor recommended by the EMA for adults with metastatic pancreatic adenocarcinoma after previous treatment.
How much did daraxonrasib extend survival?
In a 500-patient study, median survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy.
What are the common side effects of daraxonrasib?
The most common side effects of daraxonrasib are diarrhoea, rash, inflammation of the mouth lining, nausea and vomiting.
Why was the daraxonrasib review faster than usual?
The EMA reviewed daraxonrasib in phases under its Cancer Medicines Pathfinder project, so the assessment took less than 150 days.
Is daraxonrasib already available in Europe?
Not yet. The EMA recommendation for daraxonrasib needs a European Commission decision, after which each country sets price and reimbursement.



